High-flow 20% subcutaneous immunoglobulin G in patients with primary immunodeficiency disease

Ann Allergy Asthma Immunol. 2020 Sep;125(3):344-346. doi: 10.1016/j.anai.2020.05.022. Epub 2020 May 28.

Authors

Kaley McCrary¹, Jennifer W Leiding², Carla Duff³

Affiliations

¹ Office of Graduate Medication, Pediatric Residency Training Program, Department of Pediatrics, University of South Florida, St. Petersburg, Florida.
² Division of Allergy and Immunology, Department of Pediatrics, University of South Florida, St. Petersburg, Florida.
³ Division of Allergy and Immunology, Department of Pediatrics, University of South Florida, St. Petersburg, Florida. Electronic address: DUFFCM@USF.EDU.

PMID: 32473202
DOI: 10.1016/j.anai.2020.05.022

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Female
Humans
Immunoglobulin G / administration & dosage*
Immunologic Deficiency Syndromes / drug therapy
Injections, Subcutaneous / methods
Male
Middle Aged
Primary Immunodeficiency Diseases / drug therapy*
Retrospective Studies
Young Adult

Substances

Immunoglobulin G